MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of ...
pharmaphorum5y
Sanofi settles dispute with Genzyme investors over MS drug
Sanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately held back development of a multiple sclerosis drug to avoid payments ...
pharmaphorum12y
Sanofi’s Genzyme presents positive phase 3 data for MS drug
Genzyme, a subsidiary of Sanofi, has announced key data from its phase 3 clinical trials of its multiple sclerosis drug, Aubagio. The trials, called TOWER (Teriflunomide Oral in people With ...
Hosted on MSN1mon
Sanofi CEO believes company poised for growth from new drugs
NEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not facing imminent ...
Finanznachrichten1y
MediciNova, Inc.: MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
About Sanofi/Novartis litigation On March 30,2022, MediciNova, Inc. was notified that Genzyme Corporation, a subsidiary of Sanofi, filed its First Amended Complaint, which included a claim for ...